Blog
News March 4, 2021
Presage Biosciences raises $13M and inks new deal with Merck for cancer drug tests
– Seattle’s Presage Biosciences announced $13m in funding. – The funding was led by Arch Venture Partners and joined by existing investors, including Takeda Pharmaceutical, Celgene and Bristol Myers Squibb (BMS). – The company has raised a total of $35m in equity. – Presage is a biotech device company that has built a platform for testing new cancer drugs used to treat tumors.
Ratings & lists March 3, 2021
Top 20 VC funds that took part in the most Seed Stage funding rounds in Legal industry over the recent years
News March 3, 2021